11 – 20 of 23
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
A conjugation strategy to modulate antigen binding and FcRn interaction leads to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting prostate-specific antigen
- Contribution to journal › Article
-
Mark
177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging
- Contribution to journal › Article
- 2020
-
Mark
Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting
- Contribution to journal › Article
-
Mark
HER2-specific pseudomonas exotoxin a pe25 based fusions : Influence of targeting domain on target binding, toxicity, and in vivo biodistribution
- Contribution to journal › Article
-
Mark
Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules
- Contribution to journal › Article
-
Mark
Evaluating the therapeutic efficacy of mono-and bivalent affibody-based fusion proteins targeting HER3 in a pancreatic cancer xenograft model
- Contribution to journal › Article
- 2015
-
Mark
Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
- Contribution to journal › Article
- 2014
-
Mark
Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re
- Contribution to journal › Article
-
Mark
Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule
- Contribution to journal › Article
-
Mark
188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors : preclinical assessment
(2014) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 55(11). p.8-1842
- Contribution to journal › Article
